Pharmacogenomics of psychiatric drug treatment

David Pickar

Research output: Contribution to journalArticlepeer-review

Abstract

It is the goal of pharmacogenomics in psychiatry to establish predictive relationships between polymorphisms of candidate genes and therapeutic response to drug treatment. Polymorphisms of candidate genes related to drug mechanisms and pathophysiology of illness and defined clinical phenotype are the foundations for pharmacogenomic studies. Pharmacogenomic studies of antipsychotic response have focused on polymorphisms of genes for dopamine and serotonin receptors with most positive results reported for polymorphisms of genes of the 5HT2a and 5HT2c serotonin receptor subtypes. Although the goal of establishing individualized medicine predicated on an individual patient's genetic code has yet to be achieved, the fundamentals are now in place for second-generation investigation and more application to health care.

Original languageEnglish (US)
Pages (from-to)303-321
Number of pages19
JournalPsychiatric Clinics of North America
Volume26
Issue number2
DOIs
StatePublished - Jun 2003
Externally publishedYes

ASJC Scopus subject areas

  • Psychiatry and Mental health

Fingerprint Dive into the research topics of 'Pharmacogenomics of psychiatric drug treatment'. Together they form a unique fingerprint.

Cite this